Aktuelni koncepti radioimunoterapije za limfom

Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Lister TA. Follicular lymphoma: prognostic fac-tors for response and survival. J Clin Oncol 1986; 4(10): 1470−80.

Fisher RI. Overview of non-Hodgkin’s lymphoma:biology, staging, and treatment. Semin Oncol. 2003; 30(2 Suppl 4): 3−9.

Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18(17): 3135−43.

Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20(5 Suppl 5): 75−88.

Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517): 495−7.

Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malig-nancies of B cell origin. J Clin Invest 1981; 67(1): 134−40.

Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69(2): 584−91.

Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 1992; 80(6): 1502−10.

Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105(4): 1417−23.

Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma com-pared with therapy with CHOP alone: resuts of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106(12): 3725−32.

Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced fol-licular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25(15): 1986−92.

Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99(9): 706−14.

Davies AJ, Rohatiner AZ, Howell S, Britton KE, Owens SE, Micallef IN, et al. Tositumomab and iodine I 131 tositumomab for re-current indolent and transformed B-cell non-Hodgkin's lym-phoma. J Clin Oncol 2004; 22(8):1469-79. PubMed PMID: 15084620. doi: 10.1200/JCO.2004.06.055

Press OW. Radioimmunotherapy for non-Hodgkin's lympho-mas: a historical perspective. Semin Oncol 2003; 30(2 Suppl 4): 10−21.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refrac-tory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomas. J Clin Oncol 2002; 20(10): 2453−63.

Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characteriza-tion of a human B lymphocyte-specific antigen. J Immunol 1980; 125(4): 1678−85.

Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated anti-gens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63(6): 1424−33.

Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med 2010; 40(2): 122−35.

Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994; 83(5): 1390−7.

Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF. An-tibodies reactive with the B1 molecule inhibit cell cycle pro-gression but not activation of human B lymphocytes. Eur J Immunol 1986; 16(8): 881−7.

Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91(5): 1644−52.

Macklis RM. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma. Semin Radiat Oncol 2007; 17(3): 176−83.

Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10(23): 7792−8.

Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radio-immunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20(15): 3262−9.

Nourigat C, Badger CC, Bernstein ID. Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J Natl Cancer Inst 1990; 82(1): 47−50.

Mihailovic J. Y-90-ibritumomab tiuxetan therapy in lymphoma. W J Nucl Med 2006; 5(Suppl 1): S351−4.

Mihailovic J, Petrovic T. Radioimmunotherapy: A novel treatment of Non-Hodgkin's lymphoma. Arh Oncol 2010; 18(1−2): 23−9.

Iagaru A, Mittra ES, Ganjoo K, Knox SJ, Goris ML. 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) thera-py of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol 2010; 12(2): 198−203.

Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, et al. Yttrium 90-labeled ibritumomab tiuxetan radio-immunotherapy produces high response rates and durable re-missions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004; 5(2): 98−101.

Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103(12): 4429−31.

Wiseman GA, Witzig TE. Yttrium 90 (90Y) Ibritumomab Tiux-etan (Zevalin®) Induces Long-Term Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. Cancer Biother Radiopharm 2005; 20(2): 185−8.

Emmanouilides C, Witzig TE, Wieseman GA, Gordon LI, Wang H, Schilder R, et al. Safety and efficacy of Yttrium-90 inbri-tumomab tiuxetan in older patients with non-Hodgkin's lym-phoma. Cancer Biother Radiopharm 2007; 22(5): 684−91.

Vaes M, Bron D, Vugts DJ, Meuleman N, Ghanem G, Guiot T, et al. Safety and efficacy of radioimmunotherapy with 90Yttrium-rituximab in patients with relapsed CD20+B cell lymphoma: A feasibility study. J Cancer Sci Ter 2012; 4(12): 394-400.

Morschhauser F, Radford J, van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26(32): 5156−64.

Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehren-bacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19(19): 3918−28.

Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23(30): 7565−73.

Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: up-dated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96(4): 1259−66.

Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and trans-formed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18(6): 1316−23.

Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352(5): 441−9.

Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously un-treated follicular non-Hodgkin lymphoma: Southwest Oncolo-gy Group Protocol S9911. Blood 2003; 102(5): 1606−12.

Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Fiore JM, Furman RR, et al. Durable remissions from fludarabine fol-lowed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol 2004; 22(14 Suppl): 6518.

Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005; 23(24): 5696−704.

Wahl RL, Leonard JP, Kaminski MS, Goldsmith SJ. Can patients with non-Hodgkin's lymphoma (NHL) who have been treated with and responded to the BEXXAR® therapeutic regimen (tositumomab and iodine I 131 tositumomab) be retreated [abstract]. J Nucl Med 2004; 45(Suppl): 143.

Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical prac-tice. J Nucl Med 2007; 48(11): 1767−76.

Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan ra-dioimmunotherapy for relapsed low-grade, follicular, or trans-formed non-hodgkin's lymphoma. J Clin Oncol 2003; 21(7): 1263−70.

Emmanouilides CE, Czuczman MS, Revell S, Witzig TE, Wang H, Gordon LI, et al. Low incidence of treatment-related myelodys-plastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-hodgkin's lymphoma (NHL) treated with inritumomab tiuxetan. J Clin Oncol 2004; 22(14): 6696.

Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 1994; 86(19): 1450−7.

Kantarjan HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4(12): 1748−57.

Pedersen-Bjergaard J, Ersbøll J, Sørensen HM, Keiding N, Larsen SO, Philip P, et al. Risk of acute nonlymphocytic leukemia and pre-leukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985; 103(2): 195−200.

Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005; 105(12): 4576−82.

Cheung MC, Maceachern JA, Haynes AE, Meyer RM, Imrie K. I-Tositumomab in lymphoma. Curr Oncol 2009; 16(5): 32−47.

Goldsmith SJ. Radioimmunotherapy of lymphoma. In: Aktolun C, Goldsmith SJ, editors. Nuclear Medicine Therapy. Principles and Clinical Applications. New York: Business Media; 2013. p. 3−25.

Wagner HN, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, et al. Administration guidelines for radioim-munotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002; 43(2): 267−72.

Zevalin R. A physicians slide resource. Berlin: Shering AG; 2005.

Rutar FJ, Augustine SC, Kaminski MS, Wahl RL, Siegel JA, Colcher D. Feasibility and safety of outpatient Bexxar therapy (tosi-tumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma 2001; 2(3): 164−72.

Harwood SJ, Rutar F, Sullivan G, Avlonitis V. Bexxar radioim-munotherapy can be safely administered by healthcare profes-sionals with minimal whole body exposure. J Nucl Med 2003; 44: 327P.

Leahy MF, Seymour JF, Hicks RJ, Turner HJ. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24(27): 4418−25.

Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005; 11(14): 5215−22.

Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21(16): 3051−9.

Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau J, Petil-lon MO, Huglo D, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a mul-ticenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol 2010; 28(23): 3709−16.

Sharkey RM, Press OW, Goldenberg DM. A re-examination of radio-immunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood 2009; 113(17): 3891−5.